LAWRENCE, Mass. and PHILADELPHIA, Nov. 11, 2011 /PRNewswire/ -- Booth # 407 at The American Society of Nephrology (ASN)'s Kidney Week 2011 -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that its Medisystems division has won a multi-year contract to supply the Vasc-Alert™ Access Surveillance Solution to Atlantic Dialysis Management Services centers.
"Robust access surveillance is increasingly important for outcomes, center economics, and compliance under the new bundled payment system. We believe Vasc-Alert's patented, automated technology simplifies and demonstrably improves a provider's ability to be effective in this area," said Mark Florence, Vice President & General Manager at Medisystems, a NxStage Company. "This agreement builds on a successful partnership between NxStage and Atlantic and demonstrates how Atlantic employs innovative new technology to improve patient care."
"After a thorough evaluation of Vasc-Alert, we believe we can reduce our rate of thrombectomy with this product technology," said J. Ganesh Bhat, M.D., Co-Principal, Atlantic Dialysis Management Services, L.L.C. "Vasc-Alert helps advance our goal of reducing hospitalizations and catheter usage. In addition, it provides a simple and convenient way to comply with CMS requirements for access surveillance without increasing staff workload."
Vasc-Alert, a patented medical device, uses computer technology to analyze standard treatment data taken during each patient's scheduled hemodialysis treatments to screen for vascular access dysfunction. By monitoring the data for increasing pressure trends, Vasc-Alert identifies patients who are at risk of developing a stenosis that may decrease the effectiveness of treatment or put the access site at risk of thrombosis -- a blockage that prevents the flow of blood through the access and can precipitate significant medical interventions such as thrombectomy and access revision. Weekly reports that identify at-risk patients are issued to the dialysis provider and allow the dialysis staff to proactively schedule further testing on the access. Earlier detection of access issues has the potential to lead to improved access patency, fewer hospitalizations, fewer missed treatments, and less pain, anxiety and inconvenience for patients.
About Atlantic Dialysis Management Services, L.L.C.
Atlantic Dialysis Management Services, L.L.C. was established to provide new dialysis site development, day to day administration and management of dialysis services and related business development activities. Atlantic Dialysis affiliates will provide over 250,000 dialysis treatments in 2011 to an estimated 2,500 patients in New York City and Long Island.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. NxStage is leading the development of the home hemodialysis market in the US with the only portable hemodialysis machine, the System One, cleared for home use by the FDA. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com/.
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended September 30, 20011. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Kristen K. Sheppard, Esq.
VP, Investor Relations
|SOURCE NxStage Medical, Inc.|
Copyright©2010 PR Newswire.
All rights reserved